Abstract
Aim: We tested the safety and immunogenicity of a novel vaccine in patients with resected high-risk melanoma. Patients & methods: HLA-A2-positive patients with resected Stage II-IV melanoma were randomized to receive up to three vaccinations of melanoma-associated peptide (MART-1a) combined with a stable oil-in-water emulsion (SE) either with the Toll-like receptor 4 agonist glucopyranosyl lipid A (GLA-SE-Schedule 1) or alone (SE-Schedule 2). Safety and immunogenicity of the vaccines were monitored. Results: A total of 23 patients were registered. No treatment-related grade 3 or higher adverse events were observed. Increases in MART-1a-specific T cells were seen in 70 and 63% of Schedule 1 and Schedule 2 patients, respectively. Conclusion: Both vaccine schedules were well-tolerated and resulted in an increase in MART-1a-specific T cells. Clinical Trial registration: NCT02320305 (ClinicalTrials.gov).
Original language | English (US) |
---|---|
Pages (from-to) | 983-995 |
Number of pages | 13 |
Journal | Immunotherapy |
Volume | 12 |
Issue number | 13 |
DOIs | |
State | Published - Sep 2020 |
Keywords
- MART-1
- Phase I
- T cell
- glucopyranosyl lipid A
- immunotherapy
- melanoma
- peptide
- vaccine
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology